|Mr. Kenji Yasukawa Ph.D.||Pres, CEO & Representative Director||N/A||N/A||1960|
|Mr. Naoki Okamura||Chief Strategy Officer, CFO, Corp. Exec. VP & Representative Director||N/A||N/A||N/A|
|Mr. Fumiaki Sakurai||Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.||N/A||N/A||N/A|
|Ms. Linda Friedman||Gen. Counsel & VP||N/A||N/A||N/A|
|Mr. Stig Ogata||VP of Corp. Communications||N/A||N/A||N/A|
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. It offers XTANDI, an androgen receptor signaling inhibitor for the treatment of prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ transplant rejection. The company also provides Vesicare for OAB treatment; Eligard for prostate cancer treatment; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical collaboration agreement with Merck & Co., Inc. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Astellas Pharma Inc.’s ISS Governance QualityScore as of October 4, 2019 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 6; Compensation: 1.